FDA ap­proves Mirum Phar­ma's first treat­ment for rare pe­di­atric bile duct dis­ease

The FDA on Wednes­day ap­proved Mirum Phar­ma­ceu­ti­cals’ first drug, Liv­mar­li (mar­al­ix­i­bat), which is al­so the first treat­ment for life-threat­en­ing cholesta­t­ic pru­ri­tus in young pa­tients with …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER